Lead Product(s) : Mycophenolic Acid
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Mycophenolic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dry Eye Syndromes.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 02, 2021
Lead Product(s) : Mycophenolic Acid
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mycophenolic Acid
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluate Effects and Safety of Pre-load Myfortic® in Transplant Patients
Details : Mycophenolic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 15, 2011
Lead Product(s) : Mycophenolic Acid
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mycophenolic Acid
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Myfortic (Mycophenolic Acid) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Nephrotic Syndrome.
Product Name : Myfortic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 09, 2010
Lead Product(s) : Mycophenolic Acid
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mycophenolic Acid
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Attenuating Ischemia Reperfusion Injury After Living Donor Renal Transplantation
Details : Myfortic (Mycophenolic Acid) is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Kidney Transplantation.
Product Name : Myfortic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 24, 2010
Lead Product(s) : Mycophenolic Acid
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
